

BASIC RESEARCH

Growth hormone response to growth hormone-releasing peptide-2 in growth hormone-deficient Little mice

Cibele N. Peroni,¹ Cesar Y. Hayashida,¹¹ Nancy Nascimento,¹ Viviane C. Longuini,¹¹ Rodrigo A. Toledo,¹¹ Paolo Bartolini,¹ Cyril Y. Bowers,¹¹¹ Sergio P.A. Toledo¹¹

¹Biotechnology Department, National Nuclear Energy Commission (IPEN-CNEN), Cidade Universitária, São Paulo/SP, Brazil. ¹¹Faculdade de Medicina da Universidade de São Paulo, Department of Medicine, Endocrinology, Endocrine Genetics Unit/LIM 25, São Paulo/SP, Brazil. ¹¹¹Tulane University Health Sciences Center, Department of Medicine, Division of Endocrinology, Endocrine Section, New Orleans, LA/USA.

OBJECTIVE: To investigate a possible direct, growth hormone-releasing, hormone-independent action of a growth hormone secretagogue, GHRP-2, in pituitary somatotroph cells in the presence of inactive growth hormone-releasing hormone receptors.

MATERIALS AND METHODS: The responses of serum growth hormone to acutely injected growth hormone-releasing P-2 in lit/lit mice, which represent a model of GH deficiency arising from mutated growth hormone-releasing hormone receptors, were compared to those observed in the heterozygous (lit/+) littermates and wild-type (+/+) C57BL/6J mice.

RESULTS: After the administration of 10 mcg of growth hormone-releasing P-2 to lit/lit mice, a growth hormone release of 9.3 ± 1.5 ng/ml was observed compared with 1.04 ± 1.15 ng/ml in controls ($p < 0.001$). In comparison, an intermediate growth hormone release of 34.5 ± 9.7 ng/ml and a higher growth hormone release of 163 ± 46 ng/ml were induced in the lit/+ mice and wild-type mice, respectively. Thus, GHRP-2 stimulated growth hormone in the lit/lit mice, and the release of growth hormone in vivo may be only partially dependent on growth hormone-releasing hormone. Additionally, the plasma leptin and ghrelin levels were evaluated in the lit/lit mice under basal and stimulated conditions.

CONCLUSIONS: Here, we have demonstrated that lit/lit mice, which harbor a germline mutation in the *Growth hormone-releasing hormone* gene, maintain a limited but statistically significant growth hormone elevation after exogenous stimulation with GHRP-2. The present data probably reflect a direct, growth hormone-independent effect on *Growth hormone S* (ghrelin) stimulation in the remaining pituitary somatotrophs of little mice that is mediated by growth hormone S-R 1a.

KEYWORDS: Ghrelin; GH; GHRH-R; GHRP-2; Leptin; Little mouse.

Peroni CN, Hayashida CY, Nascimento N, Longuini VC, Toledo RA, Bartolini P, et al. Growth hormone response to growth hormone-releasing peptide-2 in growth hormone-deficient Little mice. Clinics. 2012;67(3):265-272.

Received for publication on November 16, 2011; First review completed on November 22, 2011; Accepted for publication on December 15, 2011

E-mail: toledo@usp.br

Tel.: 55 11 3133.9694

INTRODUCTION

The synthesis and secretion of growth hormone (GH) are primarily regulated by the hypothalamic hormones GH-releasing hormone (GHRH) and somatostatin by the negative feedback of GH and IGF-I and by the natural endogenous GH-releasing hormone ghrelin (1-8). Normal somatotroph maturation, proliferation, and somatic growth and development require GHRH (9). In the late differentiation phases of somatotroph cells, GHRH activates Gs alpha, cAMP, and the

protein kinase A pathway through its cell membrane receptor GHRH-R (1,10,11). Conversely, ghrelin, which was initially isolated from the rat stomach and hypothalamus, acts through the growth hormone secretagogue (GHS) receptor (GHS-R 1a), which is coupled to members of the Gq/i family and activates phospholipase C (2,12,13).

Synthetic GHSs are ghrelin receptor agonists that stimulate GH secretion in vitro and in vivo. They include GH-releasing peptides (GHRPs), such as GHRP-2, and non-peptide compounds. Synthetic GHSs and ghrelin also stimulate ACTH/cortisol and prolactin release via hypothalamic effects and have been shown to increase food intake, energy expenditure, sleep and cardiac tone (15-17). Although their chemical structures vary, all GHSs seem to act through the GHS-R to enhance GH secretion and food intake. GHS-R mRNA has been identified in the pituitary gland, arcuate nucleus of the hypothalamus, and in other

Copyright © 2012 CLINICS – This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<http://creativecommons.org/licenses/by-nc/3.0/>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

No potential conflict of interest was reported.

tissues (6,15-17). For maximal GH stimulation, GHRPs require a simultaneous secretion of hypothalamic GHRH (18-21). Furthermore, ghrelin and synthetic GHSs potentiate GHRH-induced cAMP production and increase the levels of several GHRH-Rs, which may also result in altered interactions between GHS-R and GHRH (22-25). In this context, a dual and complementary action of ghrelin and GHRP on the hypothalamus and pituitary gland may occur. Furthermore, a paracrine effect on the arcuate nucleus of the hypothalamus, which is involved in food intake and energy expenditure regulation, should be mentioned (17).

The predominant site of action of GHSs for GH secretion has not been fully established. GHS-Rs have been identified in both the pituitary gland and the hypothalamus, and GHSs may act at either or both sites. Some evidence indicates that the GH-secreting action of GHSs and ghrelin may occur mainly in the hypothalamus, with a marginal direct effect on the pituitary gland (25-27). Accordingly, a limited but statistically significant GH elevation ($p < 0.05$) was first documented following an acute stimulus with GHRP2 in GH-deficient patients with short stature resulting from a germline mutation in the *GHRH-R* gene (28). Soon after, other studies supported these initial findings (29,30), which indicates a direct action of GHRP-2 in the pituitary gland. The cloning of the mouse and human growth hormone-releasing hormone receptor gene (*ghrhr*) was accomplished following the finding that different mutations analogous to the *ghrhr* Asp60Gly inactivating mutation of GH-deficient little mice also occurred in GH-deficient humans (31-37). The *ghrhr* mutation in lit/lit mice resulted in a complete lack of GHRH-mediated GH release, which was further supported by the finding that the mutated GHRH-R protein did not bind to GHRH (32,33). As expected, the complete lack of a GH response to GHRH1-29NH₂ has been reported in little mice (38-40). The complete lack of a GH response to GHRP-6 was also reported in little mice (41). Nevertheless, because GHSs act specifically through the GHS-R, it is reasonable to assume that a GH response may occur in response to a GHS challenge in little mice. In support of this hypothesis, GHRP-2 has been shown to increase the GH release from rat pituitaries *in vitro*, even after the GHRH-R was blocked using the antisense oligonucleotide approach (42).

The little mouse is an established animal model for assessing the direct GHRH-independent effects of GHSs and ghrelin on pituitary somatotroph cells (33-35). Here we evaluated the GH response to GHRP-2 in little mice (lit/lit), their heterozygous (lit/+) littermates, and wild-type (+/+) controls. Additionally, a possible role of GHRH and GHRH-R on the secretion and action of ghrelin was evaluated by measuring the fasting and fed plasma ghrelin and serum leptin levels in these animals.

MATERIALS AND METHODS

Animals and housing conditions

Little mice (C57BL/6J lit/lit) and their heterozygous (lit/+) littermates were purchased from The Jackson Laboratory (Bar Harbor, ME, USA), and a breeding colony was established in our animal house (43). Mutant mice were produced by mating C57BL/6J lit/lit females to C57BL/6J lit/+ males. Mice of both sexes at 45-90 days of age were used in the assays. As controls, wild-type (+/+) C57BL mice, obtained from the Tropical Medicine Division, University of

São Paulo School of Medicine (São Paulo, Brazil), were used at 45-90 days of age (body weight ~30 g). The body weights of the lit/lit and lit/+ mice were approximately 10-12 g and 20-25 g, respectively, at the same age and were obtained by a sensitive method (43).

The mice were maintained in an air-conditioned room at a temperature of $24 \pm 1^\circ\text{C}$. Water and food were provided *ad libitum*, and light was regulated on a 12-h light/12-h dark schedule.

A group of mice was kept under fasting conditions by removing food in the afternoon at approximately 17:00 h. Blood was collected from the fasted and non-fasted mice groups the following day at 09:00 h. Water was provided *ad libitum* to the fasted mice (43).

This research was approved by the local ethics committee and met the criteria for animal experiments.

Sequencing analysis

Genotyping was performed to confirm and genetically characterize the lit/lit, lit/+, and wt/wt mice. The mice were genotyped by the PCR amplification of tail DNA isolated using the standard phenol protocol of our laboratory (44,45). Two primers, 5'-TGAGCTTGCATGTCTTCA-GG-3' and 5'-GGGATTAGACCAGCCAGTGA-3' (annealing temperature, 60°C), were used to amplify the gene region of the *ghrhr* Asp60Gly mutation that results in the little mouse phenotype (24). The mutation analysis was performed by automated sequencing using the Big Dye Terminator v3.1 (310 Sequencer, Applied Biosystems, Foster City, CA, USA).

The forward and reverse strands were analyzed in duplicate DNA samples. Two sequencing editor software programs (Gene Studio™ Professional Edition, Suwanee; and Mutation Surveyor, Softgenetics, PA, USA) were used to identify DNA abnormalities.

Preparations and injections

GHRP-2 (200 µg/ml; lot KP102-HQ007; Pramorelin: D-alanyl-3-(2-naphthyl)-D-alanyl-L-alanyl-L-tryptophyl-D-phenylalanyl-L-lysine dihydrochloride) was obtained from Fujisawa USA, Inc. (Deerfield, IL). The mice were given intra-peritoneal (i.p.) injections and weighed. Depending on the experimental design, blood samples were collected from the orbital sinus for the measurements of GH, IGF-I, leptin, or ghrelin.

Immunoassays

The mouse GH (mGH) serum levels were determined by a highly sensitive in-house specific RIA using reagents obtained from Dr. A. F. Parlow of the National Hormone and Pituitary Program (NHPP, Torrance, CA) (46). All samples were assayed in duplicate. In each assay, pools of wt/wt C57BL and lit/lit mice sera were used as internal controls. Eight mice from each strain were used, and the pooled ($n = 8$) serum level of GH was 1.3 ± 0.7 ng/ml in the lit/lit mice and 6.5 ± 1.8 ng/ml in the wt/wt C57BL mice. The initial GH levels in the lit/+ mice were not significantly different from those in the wt/wt C57BL mice, probably because of the number of animals. The sensitivity of the GH assay, which was performed via a delayed tracer addition, was 0.25 ± 0.15 ng/ml as calculated according to Rodbard's definition (47). The inter-assay coefficient of variation was less than 10%.

Levels of IGF-I were determined in duplicate using a rat IGF-I RIA kit (DSL-2900, Diagnostic Systems Laboratories

Inc., Webster, Texas, USA) with a minimum detection level of 21 ng/ml and measurable concentrations ranging from 150 to 4,500 ng/ml.

Leptin levels were determined using a rat leptin RIA kit (Linco Research Inc., St. Charles, MO, USA) with a minimum detection value of 0.2 ng/ml and a measurable concentration range of 0.2-12.8 ng/ml.

Total ghrelin (octanoylated + desoctanoylated)(48) levels were determined using a rat ghrelin RIA kit (Phoenix Pharmaceuticals Inc., Belmont, CA, USA) with a sensitivity of ~5.4 pg/tube and a range of 1-128 pg/tube. Active ghrelin (octanoylated) levels were determined using the Linco Research kit (St. Charles, MO). For these measurements, blood samples were collected in tubes containing 0.78 mg K₂EDTA (250-500 ml blood/tube), kept on ice and spun in a refrigerated centrifuge. PMSF (0.1 mg/ml plasma) and 1 M HCl (50 ml/ml plasma) were added to the plasma samples. The samples were kept frozen at -70°C until the ghrelin levels were measured. For the active ghrelin kit, the intra- and inter-assay coefficients of variation were 6.5-9.5% and 9.6-16.2%, respectively. For the total ghrelin kit, the intra- and inter-assay coefficients of variation were <10% and <15%, respectively.

Study design

Two groups of age-matched, wild-type (+/+) C57BL mice were initially injected i.p. with either 1 µg (32 animals/group) or 10 µg (18 animals/group) GHRP-2, and blood samples for the GH measurements were collected at different times up to 1 h after injection. Three mice were used for each time point, and the blood was withdrawn only once before the animals were sacrificed. In a pilot study, 10 µg GHRP-2 was administered i.p. to 2-3 lit/lit, lit/+ and (wt/wt) mice (n=18 animals/group), and the GH response was measured at different times up to 1 hour after injection to assess the effects of dose and timing.

An independent two-week study was performed with lit/lit mice treated daily with 10 µg GHRP-2 i.p. per mouse (n=6 mice for the control and n=8 mice for the experimental group). The body weight was measured, and blood was drawn every 3-4 days to measure the GH, IGF-I and leptin levels. As previously described, the body weight was measured using a precise, highly sensitive methodology (40). Briefly, animal body weights were measured daily throughout the entire experiment and then used to calculate individual growth curves; the slopes of the growth curves were then used as response parameters. For the lit/lit mice, the acceptable daily weight variation in the last ten days before each assay (pre-assay period) was within 0.0025 ± 0.0045 g/day (36,40). Thus, approximately 10% of the homozygous dwarf mouse population was rejected. Our criteria for selecting the lit/lit mice were based on the growth curves of the homozygous (lit/lit) and heterozygous (lit/+) mice of the C57BL/6J strain, which had already been established in a previous study (36) and further confirmed by the genotyping performed here.

To evaluate and compare the areas under the curve of the hormonal values, an arbitrary unit of concentration (ng/ml/time (min)) was defined.

Statistics

To analyze the leptin levels and hormonal responses as measured by the area under the curve (AUC) data, a two-way analysis of variance (ANOVA) was performed with

time and treatment as the independent variables. Student's t-test with Bonferroni's adjustment was used for all values obtained after initiation of treatment. In all other measurements, Student's paired t-test was used to evaluate the significance of differences. $p < 0.05$ was considered to be significant.

RESULTS

ghrhr mutation analysis

DNA was extracted from a blood sample of a lit/lit mouse using routine methods described elsewhere (44,45). PCR using previously reported primers was performed, followed by the sequence analysis of the *ghrhr* gene.

A germline homozygous *ghrhr* Asp60Gly mutation was confirmed in the lit/lit mouse, whereas a heterozygous *ghrhr* Asp60Gly mutation was verified in the lit/+ littermates. Conversely, wild-type (+/+) C57BL/6J mice did not harbor this germline mutation (Figure 1). These data confirmed the genotypes of the three mice lineages used in the present study, respectively: +/+, Asp60Asp; lit/+, Asp60Gly and lit/lit, Gly60Gly (Figure 1).

Basal GH and IGF-I levels in normal and homozygous mice

The mean basal mGH levels in the 18 homozygous lit/lit mice (1.16 ± 0.97 ng/ml; range, 0.28-4.0 ng/ml) were significantly lower than those observed in the 46 wild-type (+/+) controls (5.36 ± 2.60 ng/ml; range, 1.05-14.0 ng/ml; $p < 0.001$) or their 12 heterozygous (lit/+) littermates (6.60 ± 2.35 ng/ml; range, 4.25-11.5 ng/ml; $p < 0.001$). Furthermore, the basal GH concentrations observed in the lit/+ and +/+ mice did not differ significantly.

The basal serum IGF-I value in the 8 lit/lit mice (231 ± 103 ng/ml; range, 120-420) was clearly lower than that in the 8 +/+ controls (473 ± 104 ng/ml; range, 330-560 ng/ml; $p < 0.001$).

Response of GH to acute GHRP-2 administration

It was initially shown that the increase of GH in the C57BL wild type control mice in response to 1 µg GHRP-2 was significantly less (~two-fold increase over basal levels) than the increase in response to 10 µg of i.p. GHRP-2 (24-fold increase over baseline values; $p < 0.05$). Thus, the 10-µg GHRP-2 dose was selected for the assessment of the GH responses in the three groups of mice (+/+, lit/+ and lit/lit).

The mean peak GH response in the control group (+/+) was 163 ng/ml, and it occurred 10 min after the administration of GHRP-2 with a 24-fold increase over the baseline levels (Figure 2). In the lit/+ and lit/lit mice, there was a significant GH response to GHRP-2 at 5-10 min. Twenty minutes after GHRP-2 injection, GH levels returned to the baseline values.

These data indicate that the GH response to 10 µg GHRP-2 (9.3 ± 1.5 ng/ml; range 8-11 ng/ml) observed in the homozygous lit/lit mice was significantly higher than that in the saline-injected lit/lit mice (1.04 ± 1.15 ng/ml; $p < 0.001$). Furthermore, the response of GH to GHRP-2 in the lit/lit mice was significantly lower than that observed in the heterozygous (lit/+) littermates (9.3 ± 1.5 ng/ml vs. 34.5 ± 9.7 ng/ml; $p < 0.01$) or in the wild type (+/+) mice (163 ± 46 ng/ml; $p < 0.005$). Thus, the GH response to GHRP-2 in the lit/+ mice was intermediate to those observed in the lit/lit and +/+ mice (Figure 2).




Figure 1 - The germline *ghrh-r* Asp60Gly mutation analysis was performed by PCR amplification and direct automated sequencing. The chromatogram traces show the GAT/GAT (wild-type), GAT/GGT (heterozygous mouse) and GGT/GGT (little mouse) statuses, thus characterizing the genotype of the three mice strains used in this study. The forward and reverse traces are shown in the top and bottom panels, respectively.

The absolute GH increases over the baseline in the lit/lit, lit/+, and +/+ mice were 8.3, 28.8, and 156 ng/ml, respectively, which confirms the marked differences in GH secretion among the three studied mice strains. The increase in the GH level over the baseline following the acute administration of 10 µg GHRP-2 did not differ significantly between the lit/lit and lit/+ mice (8.9- vs. 6.1-fold; $p > 0.05$). However, the increase in GH in response to GHRP-2 was significantly decreased in the lit/lit ($p < 0.005$) and lit/+ mice ($p < 0.01$) compared with the controls. The

individual areas under the curve (AUCs) of the serum GH in response to the acute administration of GHRP-2 further confirmed the significant differences between the GHRP-2- and saline-treated lit/lit mice (Figure 3).

Responses to the two-week administration of GHRP-2

As expected, a marked increase in body weight was observed in the lit/lit mice when 10 µg GHRP-2 was i.p. injected (49) once a day for two weeks in comparison to injection of the control vehicle ($p < 0.02$; Figure 4). However, GH and IGF-I levels did not significantly increase during the two-week administration of GHRP-2 (data not shown). Furthermore, markedly elevated ($p < 0.005$) leptin levels in the lit/lit mice were observed on day 15 of the GHRP-2 treatment.

■, lit/lit injected with saline; ▣, lit/lit injected with GHRP-2; ▲, lit/+ injected with GHRP-2; ○, +/+ injected with GHRP-2.




Figure 2 - Mouse GH (mGH) serum concentrations were determined by a sensitive RIA method (detection limit, 0.25 ng/ml). Shown here are the mGH increases after the acute administration of 10 µg GHRP-2 in lit/lit, lit/+ and +/+ mice as well as the saline injection of lit/lit mice. Three animals were used for each time point only once each and then sacrificed. In total, 18 animals were used for each of the four observations, and 72 animals were used in total.

Serum ghrelin and leptin levels

The concentrations of plasma acyl ghrelin and total (acyl + deacyl) ghrelin, which may have independent and inter-related biological actions, and the concentrations of serum leptin in the +/+, lit/+, and lit/lit mice in the fasted and fed state are shown in Table 1. In the fasted state, the mean plasma acyl ghrelin and total ghrelin levels in the lit/lit mice were significantly lower (by 78.9% and 37.6%, respectively) than in the +/+ mice. The heterozygous lit/+ mice also had significantly lower levels of fasting acyl ghrelin and total ghrelin (by 80.5% and 44.9%, respectively) compared with the controls. In the lit/lit mice, the plasma acyl ghrelin in the fed state was 93.8% higher than in the fasted state. Conversely, in the wild-type mice, the plasma acyl ghrelin was 82.5% lower ($p < 0.001$), and total ghrelin was 61% lower ($p < 0.001$) in the fed state than in the fasted state. The difference in the fed-state plasma acyl ghrelin levels between the two groups (157 ± 70 pg/ml for +/+ mice vs. 67 ± 18 pg/ml for lit/lit) was significant ($p < 0.05$). Furthermore, the total ghrelin levels were 23.4% higher in the fasted state than in the fed state for the lit/lit mice.




Figure 3 - Serum mGH responses to the acute administration of 10 µg GHRP-2 (or saline, SAL for lit/lit mice) in the lit/lit, lit/+, and +/+ mice expressed as the areas under the curve (AUCs). An arbitrary unit (ng/ml/min) was used to allow evaluation of the AUC. The animal experiments are as shown in Figure 2.

The serum leptin levels of the fasted lit/lit mice were 348% higher than those in the fasted +/+ mice ($p < 0.005$). The fasted lit/+ mice also differed from the lit/lit (50% lower, $p < 0.02$) and +/+ mice (123% higher, $p < 0.005$). Moreover, in the lit/lit mice, the serum leptin levels in the fed state decreased by 35% compared with the fasted state ($p > 0.05$). Additionally, leptin levels in the fed lit/+ and +/+ fed mice were 37% and 16% higher than in the fasted animals, respectively ($p > 0.05$).

DISCUSSION

Several spontaneous homozygous germline mutations in mice that result in the deficiency of pituitary hormones and dwarfism have been documented (34). Thus, the phenotypes of the Ames dwarf mice result from mutations in the *Prop1* gene and present a congenital deficiency of multiple pituitary hormones, including GH (50). In addition, Snell dwarf mice with mutations in the *pit* gene have dwarfism

arising from GH deficiency, hypothyroidism, and infertility (51). Furthermore, the little mice phenotype results from homozygous mutations in the *ghrh-r* gene (33). Equivalent germline homozygous mutations in the *PRO1*, *PIT*, and *GHRH-R* genes have been reported in humans presenting with severe short stature (37,52,53).

GHRH-R mutations have been specifically suggested to cause the absence of a GH response to GHRP-2 in humans (54). However, several other studies documented a limited but statistically significant increase in GH after the administration of GHRP-2 to these patients (28-30). Similarly, it has been suggested that the little mouse is resistant to the action of GHRP-2 and does not present an increase in GH after the administration of this peptide (41). Thus, the main goal of the present study was to investigate whether little mice have an absolute resistance to the action of GHRPs, as previously described, or if they present a statistically significant GH response to one of the GHRPs, i.e., GHRP-2, as observed in humans. To detect minor GH variations in the serum, we used an improved mGH method to better discriminate possible GH increases after the administration of GHRP-2.

To our knowledge, no other paper to date has specifically re-investigated this issue in little mice. Of note, complete GH resistance to GHRP-2 in *ghrh*-knockout mice has been documented. However, the *ghrh*-knockout mice and little mice have mutations in different genes, although their phenotypes are similar. Furthermore, different GH methods and experimental conditions may have influenced these apparently contradictory results.

GH responses to GHRP-2

The development and function of somatotroph cells are GHRH-dependent (1), as indicated by our findings of a limited GH response to acute GHRP-2 administration in lit/lit mice carrying a homozygous mutation in *ghrh*. Assuming that *ghrh* is completely inactive in lit/lit mice (39), our present findings indicate that at least some GHRH-independent GHS-GH release occurs through the activation of the GHS-R.

In addition to mature GHRH-dependent somatotrophs, GH-producing stem cells have been found in the pituitary glands of lit/lit mice and in 60-day-old adult mice (26).

- saline, slope=0.0025 g/mouse/day ($r=0.2786$)
- GHRP-2, slope=0.0328 g/mouse/day ($r=0.9579$, $p < 0.02$)




Figure 4 - The weight gain assay upon the chronic administration of 10 µg/animal/day GHRP-2 in the lit/lit mice; eight animals were used in this experiment (n=8). The control group was injected with saline; six lit/lit mice were used in this experiment (n=6). The mean and standard error of the mean intervals are shown.

Table 1 - The plasma ghrelin and serum leptin concentrations in fed and 16-hour-fasted little (lit/lit), heterozygous (lit/+), and wild-type (+/+) mice.

Mouse strain	Bioactive ghrelin (pg/ml)		Total ghrelin (pg/ml)		Leptin (ng/ml)	
	fed	fasted	fed	fasted	fed	fasted
+/+	67 ± 18.2 ⁽⁶⁾	384 ± 100	1272 ± 410 ⁽⁷⁾	3261 ± 222	2.70 ± 0.32 ⁽⁸⁾	2.32 ± 0.60
lit/+	85 ± 14.2 ^(NS)	75 ± 3.0 ⁽¹⁾	1538 ± 96.0 ^(NS)	1796 ± 540 ⁽²⁾	7.09 ± 5.0 ⁽⁹⁾	5.18 ± 0.72 ⁽²⁾⁽⁵⁾
lit/lit	157 ± 70 ^{(4) (10)}	81 ± 21.8 ⁽²⁾	2513 ± 384 ⁽¹¹⁾	2036 ± 706 ⁽³⁾	6.78 ± 3.74 ⁽¹²⁾	10.40 ± 2.62 ⁽²⁾

All measurements are derived from the average ± SD of n=4 animals/group.

(1) $p < 0.001$, (2) $p < 0.005$, (3) $p < 0.02$, (4) $p < 0.05$, NS = non-significant, all compared to +/+; (5) $p < 0.02$ compared to lit/lit; (6) $p < 0.001$ compared to fasted; (7) $p < 0.001$ compared to fasted; (8)-(12) all NS compared to the corresponding fasted animals.

However, it is not known whether GHRP-2 and/or ghrelin act as a trophic factor for the GH-producing stem cells independently of the pituitary action of GHRH.

The previously reported lack of a GH response in lit/lit mice to another type of GHS, GHRP-6 (41), may be related to the use of a less sensitive GH assay (10 ng/ml vs. 0.25 ng/ml for our assay). Furthermore, GHRP-2 has a greater biological potency (approximately six-fold greater) than GHRP-6 for triggering the release GH (14-16). The absence of GH responses to GHRP-6 was also initially suggested in humans with a Glu72Stop *GHRH-R* mutation (42). However, several other studies have documented the presence of a statistically significant, although impaired, GH response to GHRP-2 in patients with genetic short stature who harbor a severely truncated *GHRHR* gene (28-30).

Furthermore, neither acute nor chronic GH elevations were noticed in *ghrh*-knockout mice, and it was concluded that GHRP-2 has a growth-stimulating effect that augments the response induced by JI-38 (55,56). However, it is important to note that a) knockout mice and animals harboring similar or even equivalent spontaneous germline mutations may behave differently; b) the mGH methods used to study the little mice and knockout mice could be different; and c) different experimental designs were used in these studies (28-30,55,56).

The intermediate GH responses to GHRP-2 in the lit/+ mice may be the result of qualitative and/or quantitative differences in the somatotroph cells, although further research on this topic should be conducted to confirm these findings. These data may suggest a genetic dosage effect on somatotroph cell function, which would become more impaired as a function of age. Similarly, a genetic dosage effect was previously proposed for cases carrying a mutation in the *GHRHR* gene (52).

Importantly, our GH RIA method was able to detect the presence of very low GH levels (~0.25 ng/ml) in little mice with acceptable precision; similar data are seldom available in the literature. GH kits with lower sensitivities have been used by others. However, no other reports were found that addressed the serum GH levels of lit/lit mice obtained by a specific homologous RIA. Cheng et al. reported serum GH levels of 0.61 ± 0.09 ng/ml in male and female lit/lit mice and 8.50 ± 0.75 ng/ml and 2.85 ± 0.33 ng/ml in male and female lit/+ mice, respectively. Marmary et al. reported serum GH levels of 1.08 ± 0.06 ng/ml and 20.35 ± 22.9 ng/ml in Snell dwarf mice and their control littermates, respectively (58). High estimates of the absolute level of serum GH determined using a heterologous rat GH RIA have also been reported (59,60).

Growth following GHRP-2 administration

In this study, a definite increase in the body weight of little mice was observed after the administration of GHRP-2.

These findings are in agreement with other studies that documented a significant body weight gain in *ghrh*-knockout mice treated with GHRP-2 and in mice after the administration of ghrelin, which shows that both peptides induce adiposity in these animals (61). Of note, Alba et al. did not observe an increase in the longitudinal growth of *ghrh*-knockout mice during a six-week treatment with GHRP-2 at a dose of 10 µg injected subcutaneously (s.c.) twice a day, which confirmed the pivotal role of GHRH in GH secretion and subsequent body growth (48). Additionally, a chronic six-week treatment with 10 µg s.c. GHRP-2 did not increase the acute GH response (30-min). This apparent discrepancy with our findings may have resulted from differences in the time of blood collection or GH assay sensitivity, different methods of drug administration (s.c. vs. i.p.), or a combination of these factors.

Leptin and ghrelin levels in the lit/lit mice

We also evaluated whether GHRP-2 would influence leptin and ghrelin levels.

The fasting levels of acyl ghrelin and total ghrelin were higher in the wild-type +/+ mice than in the fed mice (61-63). The physiological regulation of the plasma ghrelin (i.e., its increase and decrease in the fasting and fed states, respectively) was different in the lit/lit mice. This finding may be the result of a lack of effect of the action of GHRH and its inactive GHRH-R, although this hypothesis should be tested further.

High basal serum leptin levels and an additional increase after prolonged GHRP-2 administration in lit/lit mice have also been observed in mice treated with ipamorelin (34). These findings are considered to reflect the increased adipose tissue mass in GH-deficient mice and the adipogenic effect of GHRP-2 and ghrelin (61-63).

To investigate the lipogenic effects of these peptides in mice, the doses of GHRP-2 used in the present study were similar to those used by Tschop et al. and to the GHRP-6 doses used by Jansson et al. and Lall et al. (38,49,61). However, based on body weight, such doses were proportionally much higher than those tested in humans with a *GHRH-R* mutation, which could reflect interspecies differences in the sensitivity to GHSs (61).

Our limited data on the octanoyl ghrelin (ghrelin) and serum leptin levels in fed vs. fasted (17 h) wild-type (+/+) and lit/lit mice (-/-) may suggest dysfunctional relationships between these two metabolic hormones. As expected, the plasma ghrelin levels were normal in the fed wild-type mice and elevated in the fasted wild-type mice, although the opposite effect was also observed, as ghrelin and leptin were elevated in the fed state and did not further increase in the fasted state. Additionally, the results in the lit (+/-) mice partially paralleled those obtained in the lit (-/-) mice in that

the plasma ghrelin levels did not increase with fasting, and during fasting, the serum leptin levels remained elevated in the fed and fasted lit (+/- and -/-) mice. However, the limited number of studied animals prevented further conclusions from being drawn. Finally, the measurement of total ghrelin as an indicator of octanoyl ghrelin levels may be problematic. Although the total and octanoylated ghrelin levels may partially parallel each other, this agreement becomes less evident under pathophysiological conditions, such as in the present mouse study. Increasing evidence supports the biological activity of the desoctanoyl ghrelin molecule and thus in turn supports the measurement of the plasma desoctanoylated ghrelin levels by a specific assay, such as that published by Akamizu et al. (64).

In conclusion, our findings are the first to document the presence of statistically significant increases in GH following the administration of GHRP-2 in little mice. The data give further support to a direct action of GHRP-2 in the pituitary glands of little mice. Furthermore, the heterozygous lit/+ mice may have subtle disturbances in their GHRH/GHRH-R/GH axis, which suggests a genetic dosage effect, although additional data are needed to confirm this conclusion.

ACKNOWLEDGMENTS

We acknowledge Cristina T. Kanamura, B.S., and Venâncio A. F. Alves, M.D., from the Division of Pathology, Institute Adolfo Lutz, São Paulo, for technical support. We would like to thank Dr. Heitor F. Andrade Jr., who provided the C57BL wt/wt animals. This research was partially supported by FAPESP (01/11091-0). S.P.A.T. and P.B. are National Research Council (CNPq) researchers. R.A.T. is recipient of a FAPESP post-doctoral fellowship (2009/15386-6). SPAT is recipient of a CNPq fellowship and grant (401990/2010-9).

AUTHOR CONTRIBUTIONS

Peroni CN, Nascimento N, and Bartolini P performed the experiments and collaborated in the manuscript preparation. Hayashida CY collaborated in the manuscript writing. Toledo RA and Longuini VC performed the genetic analyses. Bowers CY collaborated with the product testing (ghrp-2), the measurements of ghrelin and leptin and the preparation of the manuscript. Toledo SP wrote and coordinated the research project and was the senior researcher responsible for preparing the manuscript.

REFERENCES

1. Mayo KE, Miller TL, De Almeida V, Zheng J, Godfrey PA. The growth hormone-releasing hormone receptor: signal transduction, gene expression, and physiological function in growth regulation. *Ann N Y Acad Sci*. 1996;805:184-203, <http://dx.doi.org/10.1111/j.1749-6632.1996.tb17483.x>.
2. Kojima M, Hosada H, Date Y, Nakazato M, Matsui H, Kangawa K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. *Nature*. 1999;402:656-60, <http://dx.doi.org/10.1038/45230>.
3. Nass R, Gaylinn BD, Thorner MO. The role of ghrelin in GH secretion and GH disorders. *Mol Cell Endocrinol*. 2011;340:10-4, <http://dx.doi.org/10.1016/j.mce.2011.03.021>.
4. Gahete MD, Durán-Prado M, Luque RM, Martínez-Fuentes AJ, Quintero A, Gutiérrez-Pascual E, et al. Understanding the multifactorial control of growth hormone release by somatotropes: lessons from comparative endocrinology. *Ann N Y Acad Sci*. 2009;1163:137-53, <http://dx.doi.org/10.1111/j.1749-6632.2008.03660.x>.
5. Kamenicky P, Lombès M, Chanson P. New insights in growth hormone physiology and pathophysiology. *Ann Endocrinol (Paris)*. 2010;71(Suppl 1):S25-32, [http://dx.doi.org/10.1016/S0003-4266\(10\)70004-4](http://dx.doi.org/10.1016/S0003-4266(10)70004-4).
6. Cannata D, Vijayakumar A, Fierz Y, LeRoith D. The GH/IGF-1 axis in growth and development: new insights derived from animal models. *Adv Pediatr*. 2010;57:331-51, <http://dx.doi.org/10.1016/j.yapd.2010.09.003>.
7. Veldhuis JD, Bowers CY. Determinants of GH-releasing hormone and GH-releasing peptide synergy in men. *Am J Physiol Endocrinol Metab*. 2009;296:E1085-92, <http://dx.doi.org/10.1152/ajpendo.91001.2008>.

8. Hillman JB, Tong J, Tschop M. Ghrelin biology and its role in weight-related disorders. *Discov Med*. 2011;11:521-8.
9. Frohman LA, Kineman RD, Kamegai J, Park S, Teixeira LT, Coschigano KT, et al. Secretagogues and the somatotrope: signaling and proliferation. *Rec. Prog Horm Res*. 2000;55:269-91.
10. De Almeida VI, Mayo KE. The growth hormone-releasing hormone receptor. *Vitam Horm*. 2001;63:233-76, [http://dx.doi.org/10.1016/S0083-6729\(01\)63008-5](http://dx.doi.org/10.1016/S0083-6729(01)63008-5).
11. Olsen LE, Rosenfeld MG. Perspective: genetic and genomic approaches in elucidating mechanisms of pituitary development. *Endocrinology*. 2002;143:2007-11, <http://dx.doi.org/10.1210/en.143.6.2007>.
12. Howard AD, Feighner SD, Cully DF, Arena JP, Liberators PA, Rosenblum CL, et al. A receptor in pituitary and hypothalamus that functions in growth hormone release. *Science*. 1996;273:974-77, <http://dx.doi.org/10.1126/science.273.5277.974>.
13. Horvath TL, Diano S, Sotonyi P, Heiman M, Tschop M. Minireview: ghrelin and the regulation of energy balance—a hypothalamic perspective. *Endocrinology*. 2001;142:4163-9, <http://dx.doi.org/10.1210/en.142.10.4163>.
14. Bowers CY. Growth hormone-releasing peptide (GHRP). *Cell Mol Life Sci*. 1998;54:1316-29, <http://dx.doi.org/10.1007/s000180050257>.
15. Bowers CY. GH releasing peptides (GHRPs). In: Kostyo J, Goodman H eds. *Handbook of Physiology*. New York: Oxford University Press. 1999;267-97.
16. Bowers CY. Unnatural growth hormone-releasing peptide begets natural ghrelin. *J Clin Endocrinol Metab*. 2001;86:1464-69, <http://dx.doi.org/10.1210/jc.86.4.1464>.
17. Laferrere B, Hart AB, Bowers CY. Obese subjects respond to the stimulatory effect of the ghrelin agonist growth hormone-releasing peptide-2 on food intake. *Obesity*. 2006;14:1056-63, <http://dx.doi.org/10.1038/oby.2006.121>.
18. Dickson SL, Doutrelant-Viltart O, Leng G. GH-deficient dw/dw rats and lit/lit mice show increased Fos expression in the hypothalamic arcuate nucleus following systemic injection of GH-releasing peptide-6. *J Endocrinol*. 1995;146:519-26, <http://dx.doi.org/10.1677/joe.0.1460519>.
19. Yokote R, Sato M, Matsubara S, Ohye H, Niimi M, Murao K, et al. Molecular cloning and gene expression of growth hormone-releasing peptide receptor in rat tissues. *Peptides*. 1998;19:15-20, [http://dx.doi.org/10.1016/S0196-9781\(97\)00263-5](http://dx.doi.org/10.1016/S0196-9781(97)00263-5).
20. Ribeiro AC, LeSauter J, Dupré C, Pfaff DW. Relationship of arousal to circadian anticipatory behavior: ventromedial hypothalamus: one node in a hunger-arousal network. *Eur J Neurosci*. 2009;30(9):1730-8, <http://dx.doi.org/10.1111/j.1460-9568.2009.06969.x>.
21. Tamura H, Kamegai J, Shimizu T, Ishii S, Sugihara H, Oikawa S. Ghrelin stimulates GH but not food intake in arcuate nucleus ablated rats. *Endocrinology*. 2002;143:3268-75, <http://dx.doi.org/10.1210/en.2002-220268>.
22. Bowers CY, Reynolds GA, Durham D, Barrera CM, Pezzoli SS, Thorner MO. Growth hormone (GH)-releasing peptide stimulates GH release in normal men and synergistically with GH-releasing hormone. *J Clin Endocrinol Metab*. 1990;70:975-82, <http://dx.doi.org/10.1210/jcem-70-4-975>.
23. Pandya N, DeMott-Friberg R, Bowers CY, Barkan AL, Jaffe CA. Growth hormone (GH) releasing peptide-6 requires endogenous hypothalamic GH-releasing hormone for maximal GH stimulation. *J Clin Endocrinol Metab*. 1998;83:1186-89, <http://dx.doi.org/10.1210/jc.83.4.1186>.
24. Horikawa R, Tachibana T, Katsumata M, Ishikawa H, Tanaka T. Regulation of pituitary growth hormone-secretagogue and growth hormone-releasing hormone receptor RNA expression in young dwarf rats. *Endocr J*. 2000;47:S53-S56, http://dx.doi.org/10.1507/endocrj.47.SupplMarch_S53.
25. Cunha SR, Mayo KE. Ghrelin and growth hormone (GH) secretagogues potentiate GH-releasing hormone (GHRH)-induced cyclic adenosine 3',5'-monophosphate production in cells expressing transfected GHRH and GH secretagogue receptors. *Endocrinology*. 2002;143:4570-82, <http://dx.doi.org/10.1210/en.2002-220670>.
26. Dickson SL, leng G, Dyball RE, Smith RG. Central actions of peptide and non-peptide growth hormone secretagogues in the rat. *Neuroendocrinology*. 1995;61:36-43, <http://dx.doi.org/10.1159/000126825>.
27. Popovic V, Damjanovic S, Micic D, Djurovic M, Diegez C, Casanueva FF. Blocked growth hormone-releasing peptide (GHRP-6)-induced GH secretion and absence of the synergic action of GHRP-6 plus GH-releasing hormone in patients with hypothalamopituitary dysfunction: evidence that GHRP-6 main action is exerted at the hypothalamic level. *J Clin Endocrinol Metab*. 1995;80:942-47, <http://dx.doi.org/10.1210/jc.80.3.942>.
28. Gondo RG, Aguiar-Oliveira MH, Hayashida CY, Toledo SP, Abelin N, Levine MA, et al. Growth hormone-releasing peptide-2 stimulates GH secretion in GH-deficient patients with mutated GH-releasing hormone receptor. *J Clin Endocrinol Metab*. 2001;86:3279-83, <http://dx.doi.org/10.1210/jc.86.7.3279>.
29. Maheshwari HG, Pezzoli SS, Rahim A, Shalet SM, Thorner MO, Baumann G. Pulsatile growth hormone secretion persists in genetic

- growth hormone-releasing hormone resistance. *Am J Physiol Endocrinol Metab.* 2002;282:E943-E951.
30. Roelfsema F, Biermasz NR, Veldman RG, Veldhuis JD, Frölich M, Stokvis-Brantsma WH, et al. Growth hormone (GH) secretion in patients with an inactivating defect of the GH-releasing hormone (GHRH) receptor is pulsatile: evidence for a role for non-GHRH inputs into the generation of GH pulses. *J Clin Endocrinol Metab.* 2001;86:2459-64, <http://dx.doi.org/10.1210/jc.86.6.2459>.
 31. Mayo KE. Molecular cloning and expression of a pituitary-specific receptor for growth hormone-releasing hormone. *Mol Endocrinol.* 1992;6:1734-44, <http://dx.doi.org/10.1210/me.6.10.1734>.
 32. Godfrey P, Rahal JO, Beamer WG, Copeland NG, Jenkins NA, Mayo KE. GHRH receptor of little mice contains a missense mutation in the extracellular domain that disrupts receptor function. *Nat Genet.* 1993;4:227-32, <http://dx.doi.org/10.1038/ng0793-227>.
 33. Lin SC, Lin CR, Gukovsky I, Lussis AJ, Sawchenko PE, Rosenfeld MG. Molecular basis of the little mouse phenotype and implications for cell type-specific growth. *Nature.* 1993;364:208-13, <http://dx.doi.org/10.1038/364208a0>.
 34. Beck JA, Lloyd S, Hafezparast M, Lennon-Pierce M, Eppig JT, Festing MFW, et al. Genealogies of mouse inbred strains. *Nat Genet.* 2000;24:23-5, <http://dx.doi.org/10.1038/71641>.
 35. Wajnrach MP, Gertner JM, Harbison MD, Chua SC Jr, Leibel RL. Nonsense mutation in the human growth hormone-releasing hormone receptor causes growth failure analogous to the little (lit) mouse. *Nat Genet.* 1996;12:88-90, <http://dx.doi.org/10.1038/ng0196-88>.
 36. Netchine I, Talon P, Dastot F, Vitaux F, Goossens M, Amselem S. Extensive phenotypic analysis of a family with growth hormone (GH) deficiency caused by a mutation in the GH-releasing hormone receptor gene. *J Clin Endocrinol Metab.* 1998;83:432-36, <http://dx.doi.org/10.1210/jc.83.2.432>.
 37. Salvatori R, Hayashida CY, Aguiar-Oliveira MH, Phillips JA 3rd, Souza AH, Gondo RG, et al. Familial dwarfism due to a novel mutation of the growth hormone-releasing hormone receptor gene. *J Clin Endocrinol Metab.* 1999;84:917-23, <http://dx.doi.org/10.1210/jc.84.3.917>.
 38. Jansson JO, Downs TR, Beamer WG, Frohman LA. Receptor-associated resistance to growth hormone-releasing factor in dwarf "little" mice. *Science.* 1986;232:511-2.
 39. Gaylinn BD, De Almeida VI, Lyons CE Jr, Wu KC, Mayo KE, Thorner MO. The mutant growth hormone-releasing hormone (GHRH) receptor of the little mouse does not bind GHRH. *Endocrinology.* 1999;140:5066-74, <http://dx.doi.org/10.1210/en.140.11.5066>.
 40. Clark RG, Robinson ICAF. Effects of a fragment of human growth hormone-releasing factor in normal and little mice. *J Endocrinol.* 1985;106:1-5, <http://dx.doi.org/10.1677/joe.0.1060001>.
 41. Jansson JO, Downs TR, Beamer WG & Frohman LA. The dwarf little (lit/lit) mouse is resistant to growth hormone (GH)-releasing peptide (GHRP-6) as well as to GH-releasing hormone (GRH). Program of the 68th Annual Meeting of the Endocrine Society, Anaheim, CA, 1986; p.130 (abstract).
 42. Roh SG, Chen C, Choi KC, Shrestha Y, Sasaki S. Is GHRH receptor essential to GHRP-2-induced GH secretion in primary cultured rat pituitary cells? *Endocrinology.* 2002;143:1964-47, <http://dx.doi.org/10.1210/en.143.5.1964>.
 43. Bellini MH, Bartolini P. In vivo bioassay for the potency determination of human growth hormone in dwarf "little mice". *Endocrinology.* 1993;132:2051-55, <http://dx.doi.org/10.1210/en.132.5.2051>.
 44. Lourenço DM Jr, Toledo RA, Coutinho FL, Margarido LC, Siqueira SA, dos Santos MA, et al. The impact of clinical and genetic screenings on the management of the multiple endocrine neoplasia type 1. *Clinics.* 2007;62:465-76, <http://dx.doi.org/10.1590/S1807-59322007000400014>.
 45. Toledo RA, Mendonça BB, Fragoso MCBV, Soares IC, Almeida MQ, Moraes MB, et al. Isolated familial somatotropinoma: 11q13-loh and gene/protein expression analysis suggests a possible involvement of *aiip* also in non-pituitary tumorigenesis. *Clinics.* 2010;65:407-15, <http://dx.doi.org/10.1590/S1807-59322010000400010>.
 46. Rodbard D. Statistical estimation of the minimal detectable concentration (sensitivity) for radioligand assays. *Anal Biochem.* 1978;90:1-12, [http://dx.doi.org/10.1016/0003-2697\(78\)90002-7](http://dx.doi.org/10.1016/0003-2697(78)90002-7).
 47. Bellini MH, Mathor MB, De Luca M, Cancedda R, Bartolini P. Ultrasensitive in vivo bioassay detects bioactive human growth hormone in transduced primary human keratinocytes. *J Endocrinol Invest.* 1998;21:1-6, <http://dx.doi.org/10.3109/07435809809031865>.
 48. Ghigo E, Arvat E, Muccioli G, Camanni F. Growth hormone-releasing peptides. *Eur J Endocrinol.* 1997;136:445-60, <http://dx.doi.org/10.1530/eje.0.1360445>.
 49. Lall S, Tung LYC, Ohlsson C, Jansson JO, Dickson SL. Growth hormone(GH)-independent stimulation of adiposity by GH secretagogues. *Biochem Biophys Res Commun.* 2001;280:132-38, <http://dx.doi.org/10.1006/bbrc.2000.4065>.
 50. Sornson MW, Sornson MW, Wu W, Dasen JS, Flynn SE, Norman DJ, O'Connell SM, et al. Pituitary lineage determination by the Prophet of Pit-1 homeodomain factor defective in Ames dwarfism. *Nature.* 1996;384:327-33, <http://dx.doi.org/10.1038/384327a0>.
 51. Li S, Crenshaw EB 3rd, Rawson EJ, Simmons DM, Swanson LW, Rosenfeld MG. Dwarf locus mutants lacking three pituitary cell types result from mutations in the POU-domain gene *pit-1*. *Nature.* 1990;347:528-33, <http://dx.doi.org/10.1038/347528a0>.
 52. Hayashida CY, Gondo RG, Ferrari C, Toledo SP, Salvatori R, Levine MA, et al. Familial growth hormone deficiency with mutated GHRH receptor gene: clinical and hormonal findings in homozygous and heterozygous individuals from Itabaianinha. *Eur J Endocrinol.* 2000;142:557-63, <http://dx.doi.org/10.1530/eje.0.1420557>.
 53. Parnasetti F, Toledo SP, Vasilyev VV, Hayashida CY, Cogan JD, Ferrari C, et al. Impaired adrenocorticotropin-adrenal axis in combined pituitary hormone deficiency caused by a two-base pair deletion (301-302delAG) in the prophet of Pit-1 gene. *J Clin Endocrinol Metab.* 2000;85:390-7, <http://dx.doi.org/10.1210/jc.85.1.390>.
 54. Maheshwari HG, Rahim A, Shalet SM, Baumann G. Selective lack of growth hormone (GH) response to the GH-releasing peptide hexarelin in patients with GH-releasing hormone receptor deficiency. *J Clin Endocrinol Metab.* 1999;84:956-59, <http://dx.doi.org/10.1210/jc.84.3.956>.
 55. Fintini D, Alba M, Schally AV, Bowers CY, Parlow AF, Salvatori R. Effects of combined long-term treatment with a growth hormone-releasing hormone analogue and a growth hormone secretagogue in the growth hormone-releasing hormone knock out mouse. *Neuroendocrinology.* 2005;82:198-207, <http://dx.doi.org/10.1159/000092520>.
 56. Alba M, Fintini D, Bowers CY, Parlow AF, Salvatori R. Effects of long-term treatment with growth hormone-releasing peptide-2 in the GHRH knockout mouse. *Am J Physiol Endocrinol Metab.* 2005;289:E762-E767, <http://dx.doi.org/10.1152/ajpendo.00203.2005>.
 57. Cheng TC, Beamer WG, Phillips JA, Bartke A, Mallonee RL, Dowling C. Etiology of growth hormone deficiency in Little, Ames and Snell dwarf mice. *Endocrinology.* 1983;113:1669-78, <http://dx.doi.org/10.1210/endo-113-5-1669>.
 58. Marmay Y, Parlow AF, Goldsmith CM, He X, Wellner RB, Satomura K, et al. Construction and *in vivo* efficacy of a replication-deficient recombinant adenovirus encoding murine growth hormone. *Endocrinology.* 1999;140:260-65, <http://dx.doi.org/10.1210/en.140.1.260>.
 59. Hammer RE, Palmiter RD, Brinster RL. Partial correction of murine hereditary growth disorder by germ line incorporation of a new gene. *Nature.* 1984;311:65-7, <http://dx.doi.org/10.1038/311065a0>.
 60. Hahn TM, Copeland KC, Woo SLC. Phenotypic correction of dwarfism by constitutive expression of growth hormone. *Endocrinology.* 1996;137:4988-93, <http://dx.doi.org/10.1210/en.137.11.4988>.
 61. Tschop M, Smiley DL, Heiman ML. Ghrelin induces adiposity in rodents. *Nature.* 2000;407:908-13, <http://dx.doi.org/10.1038/35038090>.
 62. Toshinai K, Mondal MS, Nakazato M, Date Y, Murakami N, Kojima M, et al. Upregulation of ghrelin expression in the stomach upon fasting, insulin-induced hypoglycemia, and leptin administration. *Biochem Biophys Res Commun.* 2001;281:1220-25, <http://dx.doi.org/10.1006/bbrc.2001.4518>.
 63. Tschop M, Statnich MA, Suter TM, Heiman ML. GH-releasing peptide-2 increases fat mass in mice lacking NPY: indication for a crucial mediating role of hypothalamic agouti-related protein. *Endocrinology.* 2002;143:558-68, <http://dx.doi.org/10.1210/en.143.2.558>.
 64. Akamizu T, Shinomiya T, Irako T, Fukunaga M, Nakai Y, Nakai Y, et al. Separate measurement of plasma levels of acylated and desacyl ghrelin in healthy subjects using a new direct ELISA assay. *J Clin Endocrinol Metab.* 2005;90:6-9, <http://dx.doi.org/10.1210/jc.2004-1640>.